Since their public release, Numinus and Field Trip are being compared. What is the REAL DIFFERENCE between the two in terms of Mental Health Approaches?

In this TDR Psychedelic Exclusive, we connect with Numinus Wellness (TSX: NUMI) CEO Payton Nyquvest to discuss with us the long term sustainability for companies to succeed in psychedelics including some strategies to consider to survive in the space, and how to garner more investors and avoid being undercapitalized.

We also discuss the biggest difference between Numinus Wellness and Field Trip Health, two healthcare companies that were often compared to when they first went public. Fast forward to 3 years later, we have two very different stories, with recent reports on Numinus Q4 Earnings which is on a positive scale, and Field Trip Health’s recent announcement on hiring an independent committee for strategic options signifying their market position’s decline.

With both companies being at opposite ends of the spectrum, here’s what Payton meant, as he reveals the real core value of Numinus that differentiates it from Field Trip.